As most DCIS cases are estrogen receptor-positive with tamoxifen being a therapeutic option, COL11A1-estrogen receptor interactions need to be investigated as a potential mechanism of therapeutic resistance and recurrence. The gene discussed is ESR1; the disease is ductal breast carcinoma in situ.